Evolving Ophthalmic Care: OMNI Surgical System Proves Effective for Glaucoma, TearCare Technology Provides Relief for Dry Eye Disease

Published / Modified Apr 02 2024
CSIMarket Team / CSIMarket.com

In a remarkable breakthrough for the field of ophthalmology, Sight Sciences showcased the remarkable results of their GEMINI Trial and the cross-over phase of the SAHARA RCT at the prestigious 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. This pivotal event marked the unveiling of the OMNI Surgical System's long-term efficacy in treating primary open-angle glaucoma, as well as the TearCare technology's potential as a primary treatment for dry eye disease. These groundbreaking advancements have the potential to revolutionize ophthalmic care and improve the quality of life for millions of patients worldwide.

OMNI Surgical System: Revolutionizing Glaucoma Treatment

Primary open-angle glaucoma is a leading cause of irreversible vision loss worldwide, affecting over 80 million individuals. The results of the GEMINI Trial, a prospective study conducted over three years, have now confirmed the long-term efficacy of the OMNI Surgical System in treating this sight-threatening condition. The OMNI system combines the benefits of MIGS (minimally invasive glaucoma surgery) with the ability to manipulate aqueous humor outflow via multiple angles, addressing common limitations of traditional glaucoma surgeries.

The study demonstrated that the OMNI Surgical System significantly reduced intraocular pressure (IOP) and medication dependence among glaucoma patients. This groundbreaking technique offers improved safety, quicker recovery, and superior outcomes compared to conventional surgical methods. The potential to mitigate the need for long-term medication and future invasive surgeries heralds a new era in glaucoma management.

TearCare: A Breakthrough for Dry Eye Disease

Dry eye disease is a common ocular condition that affects millions worldwide, causing discomfort, blurry vision, and reduced quality of life. The findings from the SAHARA RCT's cross-over phase indicated that TearCare technology has the potential to revolutionize the management of this often chronic and challenging condition. TearCare offers a non-invasive, in-office solution for evaporative dry eye, addressing the underlying causes with precision and efficiency.

The SAHARA RCT demonstrated that TearCare effectively alleviates dry eye symptoms, demonstrating statistically significant improvements in tear film quality, tear stability, and ocular surface inflammation. By providing a comfortable and personalized treatment experience, TearCare allows physicians to optimize therapy plans and tailor treatments for each patient's unique needs, resulting in a significant improvement in their quality of life.

Implications for Ophthalmic Care:

The groundbreaking results of both the GEMINI Trial and the SAHARA RCT's cross-over phase have profound implications for ophthalmic care. The OMNI Surgical System's long-term efficacy for primary open-angle glaucoma and TearCare's effectiveness as a primary treatment for dry eye disease mark a significant shift in how patients will experience these conditions in the coming years.

The OMNI Surgical System's minimally invasive approach offers patients the benefits of improved safety, quicker recovery times, and reduced dependence on long-term medication. Glaucoma patients will now have access to a more comfortable treatment option, mitigating the severity of the disease and improving overall visual health outcomes.

For dry eye sufferers, TearCare provides a targeted treatment that addresses the root causes of the disease, improving tear film quality, and alleviating symptoms more effectively than ever before. With the ability to personalize treatment plans, physicians can now offer an individualized approach that caters to each patient's unique needs. This not only ensures better outcomes but also empowers patients to take control of their ocular health.


The unveiling of the OMNI Surgical System's long-term efficacy in treating primary open-angle glaucoma and the remarkable results of the SAHARA RCT's cross-over phase for TearCare technology have set the stage for a paradigm shift in ophthalmic care. These groundbreaking advancements have the potential to transform the lives of millions of individuals suffering from glaucoma and dry eye disease, offering improved safety, enhanced treatment outcomes, and a superior quality of life.


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com